Enanta Announces New Data on EDP-938, a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV), at the XIX International Symposium on Respiratory Viral Infections
- Lead compound shows greater than 4-log reduction in viral load in an animal model challenged with RSV
- Phase 1 clinical study for RSV expected to begin in the fourth calendar quarter of 2017
In vitro data demonstrated that EDP-938 is a potent inhibitor of both RSV-A and RSV-B activity, maintaining antiviral activity post-infection while presenting a high barrier to resistance. Further, EDP-938 maintained antiviral potency across all clinical isolates tested as well as virus that was resistant to fusion inhibitors. The compound inhibited RSV at a post-entry, replication step and maintained its activity in vitro when given 24 hours post infection. In addition, combination studies of EDP-938 with other types of RSV inhibitors, e.g. fusion inhibitors, showed synergistic antiviral effects. New in vivo data consistent with potent inhibition of the RSV virus were also presented. EDP-938 demonstrated a greater than 4-log reduction in viral load in an animal model challenged with RSV virus.
“We are particularly encouraged by the new in vivo data, and given the favorable preclinical profile for EDP-938, we look forward to initiating a phase 1 clinical study in the fourth calendar quarter of 2017,” stated
About EDP-938
EDP-938 is the lead non-fusion inhibitor discovered by Enanta for potential development for RSV. Enanta believes that its approach differentiates its compounds from fusion inhibitors currently in development for RSV because its non-fusion inhibitors target the virus replication machinery and have demonstrated high barriers to resistance against the virus in vitro. EDP-938 has been shown to reduce viral load below the level of detection in vivo. Additionally, non-fusion inhibitors have the potential of being effective at later stages of infection.
About RSV
Respiratory syncytial virus (RSV) is a virus that infects the lungs and represents a serious unmet medical need in infants and children, as well as immune-compromised individuals and the elderly. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in
About Enanta
Forward Looking Statements
This press release contains forward-looking statements, including statements with respect to the prospects for development of EDP-938 for the treatment of RSV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the discovery and development risks of early stage discovery efforts in disease areas such as RSV that currently have no therapeutic treatment; potential competition from the development efforts of others in this disease area; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key scientific personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-K for the fiscal year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20170626005582/en/
Source:
For Enanta Pharmaceuticals, Inc.
Investors
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR